Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...

A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area ...

177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is a mainstay strategy for low- to intermediate-grade metastatic neuroendocrine tumor patients. While this targeted radiopharmaceutical ...